Clinical trials: Flu
Influenza
A Human Influenza Transmission Study Using Naturally Infected Community Donors
The purpose of this study is to determine whether influenza A or B can be transmitted from adults with naturally acquired community influenza infection to healthy adult recipients under controlled inpatient exposure conditions…
- Trial name
- FLU-TIDE (NCT07814495)
- Testing
- Influenza Donor Visit, Influenza Recipient Inpatient Exposures Sessions
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Emory University
Influenza, Influenza-like Illness
Adjuvanted Influenza Vaccination Year 2 Follow-On Survey
The purpose of this study is to determine if different influenza vaccines produce different outcomes in nursing facility residents receiving the required annual influenza vaccination.
- Conditions
- Influenza, Influenza-like Illness, Influenza, Human
- Trial name
- NCT03599739
- Testing
- Influenza
- Where
- United States
- Volunteers
- 598 people, healthy volunteers welcome
- Sponsor
- Insight Therapeutics, LLC
Influenza
Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age
The present study is designed to evaluate the immunogenicity and safety of a single or double dose of the pandemic influenza candidate vaccine (GSK1562902A), administered following a two-administration schedule (21 days apart) in…
- Trial name
- NCT00397215
- Testing
- Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not), Fluarix
- Where
- 12 sites in Belgium, Italy
- Volunteers
- 437 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers
The aim of the study to assess the safety, reactogenicity, immunogenicity, and efficacy of quadrivalent inactivated subunit influenza vaccine Grippol® Quadri (NPO Petrovax Pharm, LLC, Russia) versus trivalent inactivated…
- Trial name
- NCT03849560
- Testing
- Grippol® Quadri, Grippol® Plus, trivalent (Yamagata lineage), Grippol® Plus, trivalent (Victoria lineage)
- Where
- 3 sites in Russia
- Volunteers
- 612 people, healthy volunteers welcome
- Sponsor
- NPO Petrovax
Healthy
Non-Inferiority Study Comparing the Subunit Vaccines Influvac and Agrippal in China
In the study Influvac will be compared to Agrippal, another subunit influenza vaccine that is already on the market in China. The main objective of the study is to show that both vaccines are comparable with regard to efficacy.
- Trial name
- NCT00325260
- Testing
- Influvac; subunit influenza vaccine
- Where
- China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Influenza A Infection, Influenza B Virus Infection
Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection
The goal of this observational study is to understand immune responses to viral airway infection in adults, including the elderly.
- Conditions
- Influenza A Infection, Influenza B Virus Infection, SARS CoV 2 Infection, RSV Infection
- Trial name
- NPA-DC (NCT06401720)
- Where
- 5 sites in Sweden
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Influenza
A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population
The purpose of this study is to determine whether the 2010/2011 Formulation Enzira vaccine is safe and elicits an immune response to seasonal influenza in healthy adults.
- Trial name
- NCT01113580
- Testing
- CSL's 2010/2011 Formulation of Enzira® Vaccine
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Swine Flu (Novel Influenza A H1N1) Vaccine Study
In the first half of this year a novel Influenza A H1N1 virus has resulted in an influenza pandemic. The United Kingdom has seen a particularly high incidence of disease.
- Trial name
- NCT00980850
- Testing
- Baxter Novel Influenza A H1N1 Whole Virus Vaccine, GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine
- Where
- 5 sites in United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Sarcoidosis, Influenza Vaccine
Efficacy and Safety of Influenza Vaccine During Sarcoidosis
Sarcoidosis is an inflammatory disease of unknown origin that can affect all organs, especially the lungs and mediastinum. Some location of sarcoidosis may require treatment with corticosteroids or immunosuppressors.Although…
- Trial name
- SARCOVAC (NCT01687517)
- Testing
- Seasonal influenza vaccine available for the 2012-2013 vaccine campaign
- Where
- France
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Influenza
Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model
A Phase 2, single center, randomized, double blind study evaluating the safety, efficacy, and immunogenicity of MVA NP+M1 in the H3N2 human influenza challenge model; on healthy adult volunteers.
- Trial name
- NCT03883113
- Testing
- MVA-NP+M1, Saline, H3N2 (A/Belgium/2417/2015)
- Where
- Belgium
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Influenza (Healthy Volunteers)
Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22
The primary objective of the study is to estimate the reporting rate of suspected Adverse Drug Reactions (ADRs) occurring within 7 days following routine vaccination with VaxigripTetra® and Efluelda®, respectively, during the…
- Trial name
- NCT05078060
- Testing
- Quadrivalent Influenza Vaccine, High-Dose Quadrivalent Influenza Vaccine
- Where
- 15 sites in Finland, Germany
- Volunteers
- 1,804 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions
Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18 through 60 years of age) and elderly (≥61 years of age) subjects with and without underlying medical conditions.
- Trial name
- NCT02091908
- Testing
- Novartis Investigational H5N1 vaccine, Novartis Seasonal Influenza Vaccine
- Where
- 6 sites in Germany
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Virus Diseases
Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults
Due in part to widespread availability of oseltamivir and clinical experience using oseltamivir to treat H5N1 influenza virus infections, many strains of influenza have become resistant to it.
- Trial name
- NCT00921726
- Testing
- Zanamivir, Oseltamivir
- Where
- Thailand
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Vaccination
Evaluation of a Flu Vaccination Program Directed at Pregnant Women Assisted at a Research Hospital in Italy.
Influenza is a serious Public Health problem, which causes a high number of cases and deaths worldwide each year. In Italy, about 8 million cases were reported in the 2018/2019 flu season, 809 of which were severe, with 198…
- Trial name
- NCT05785078
- Testing
- Educational session about vaccinations
- Where
- Italy
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Influenza
Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V
The study aims to evaluate the immunogenicity of a single full (0.5 mL) dose and a 0.25 mL 2-dose regime of Inflexal V in unprimed children aged 6 - <36 months, using the EMA guideline for the re-registration of the seasonal…
- Trial name
- NCT01229397
- Testing
- Inflexal V
- Where
- 2 sites in Italy
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza
Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine
The purpose of the study is to determine the amount of live virus that can be recovered from the nose of people who are vaccinated with the licensed live vaccine against H1N1, and to describe the immune response to vaccination.
- Trial name
- NCT01023776
- Testing
- A/California/07/09 live monovalent H1N1 vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Influenza, Influenza Vaccines
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
The purpose of this study is to evaluate the safety and tolerability of GSK Biologicals' vaccine GSK1557484A against pandemic avian (H5N1) influenza in adults at occupational risk of exposure to the virus.
- Trial name
- NCT01788228
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Collaboration
Collaborative Efforts to Increase Flu Vaccination
Beginning with the 2009-2010 season, influenza vaccine is universally recommended for children age 6 months to 18 years old, placing extra burden on health care providers across the U.S.
- Trial name
- CollabFlu (NCT01403649)
- Testing
- Private/public collaboration to increase flu vaccination, Usual care
- Where
- 27 sites in United States
- Volunteers
- 117,175 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Influenza
H1N1v Virus Challenge Study in Healthy Subjects
This is a study of a reverse-engineered, Good Manufacturing Practice (GMP) grade, antiviral-sensitive, influenza A/Bethesda/MM2/H1N1 virus (A/California/04/2009/H1N1-like) infection to assess the effect of pre-existing immunity…
- Trial name
- NCT04044352
- Testing
- Influenza A/Bethesda/MM2/H1N1 Challenge
- Where
- 4 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Viral Upper Respiratory Tract Infection
Randomized Controlled Trial of Vitamin D3 Supplementation for Viral Upper Respiratory Tract Infections (URI) Prevention
Background: Vitamin D has been shown to be an important immune system regulator. Vitamin D insufficiency during the winter may cause increased susceptibility to infections, particularly viral upper respiratory tract infections…
- Trial name
- NCT00656929
- Testing
- Vitamin D3
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Winthrop University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.